B. Riley analyst Neil Chatterji initiated coverage of Silk Road Medical with a Buy rating and $58 price target. Silk is a pure play in the $5B global carotid artery disease market with its less invasive transcarotid artery revascularization procedure for stroke prevention, the analyst tells investors in a research note. The firm says the company is poised to deliver 30% sales growth annually through 2024 while the shares are trading at a discount to comparable smid-cap medtech companies.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SILK:
- Silk Road Medical upgraded to Neutral from Sell at Citi
- Silk Road Medical reports Q4 EPS (34c), consensus (38c)
- Silk Road Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Outlook
- Silk Road Medical to Report Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023
- Silk Road Medical downgraded to Peer Perform from Outperform at Wolfe Research
